Eight tests for sperm DNA fragmentation and their roles in the clinic

In this issue, Agarwal and colleagues (1) have attempted the Herculean effort of sifting through hundreds of publications and several meta-analyses of those publications to answer a question that continues to plague clinicians in artificial reproduction technologies (ART) clinics. Simply stated, the question is “When is it appropriate to ask patients to spend more money to obtain a diagnosis of the status of DNA damage in the sperm as a tool for both the patient and clinician to decide on a course of treatment?”.